Pemetrexed News and Research

RSS
Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Boehringer Ingelheim files MAA with EMA for afatinib approval

Boehringer Ingelheim files MAA with EMA for afatinib approval

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

OncoMed announces data from demcizumab preclinical study on pancreatic cancer

OncoMed announces data from demcizumab preclinical study on pancreatic cancer

Study explains how FPGS increases effectiveness of pemetrexed in mesothelioma patients

Study explains how FPGS increases effectiveness of pemetrexed in mesothelioma patients

Folate, excision biomarkers not predictive for small-cell lung cancer response

Folate, excision biomarkers not predictive for small-cell lung cancer response

Lilly announces final results from ALIMTA Phase III study on NSCLC

Lilly announces final results from ALIMTA Phase III study on NSCLC

Data from Response Genetics' tests against cancer to be presented at ASCO 2012

Data from Response Genetics' tests against cancer to be presented at ASCO 2012

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

Results from Boehringer Ingelheim’s LUX-Lung 3 Phase III trial on stage IIIB or IV NSCLC

Lilly to present oncology data from more than 25 studies at ASCO annual meeting

Lilly to present oncology data from more than 25 studies at ASCO annual meeting

Results from Boehringer Ingelheim's afatinib Phase III lung cancer trial

Results from Boehringer Ingelheim's afatinib Phase III lung cancer trial

Study assesses link between antifolate medications, KRAS mutations and amplification

Study assesses link between antifolate medications, KRAS mutations and amplification

Patients with KRAS mutant NSCLC should respond well to antifolates

Patients with KRAS mutant NSCLC should respond well to antifolates

EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC

EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC

Study: Lung cancer patients with diabetes mellitus tend to live longer

Study: Lung cancer patients with diabetes mellitus tend to live longer

African Americans more likely than Caucasians to develop and die from lung cancer

African Americans more likely than Caucasians to develop and die from lung cancer

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Pemetrexed treatment produces better outcomes in ALK-translocated NSCLC patients

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review